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Table 1 Clinicopathological characters of patients of this study 
 
 Numbers (%) (n=57) 
FIGO Stage  
  IA 21 (36.8) 
  IB 11 (19.2) 
  II 6 (10.5) 
  IIIA 5 (8.8) 
  IIIB 1 (1.8) 
  IIIC1 1 (1.8) 
  IIIC2 6 (10.5) 
  IVB 6 (10.5) 
Histology  
Epithelial component  
  Endometrioid G1 16 (28.1) 
  Endometrioid G2 5 (8.8) 
  Endometrioid G3 14 (24.6) 
  Serous 13 (22.8) 
  Small cell 1 (1.8) 
	 Undifferentiated 1 (1.8) 
  Mixed 7 (12.3%) 
Mesenchymal component  
  Homologous 25 (43.9) 
  Heterologous 32 (56.1) 
Myometrial invasion  
   ≤ 1/2 35 (61.4) 
   > 1/2 22 (38.6) 
Cervical invasion  
  Absent 48 (84.2) 
  Present 9 (15.8) 
LVSI  
  Absent 33 (57.9) 
  Present 24 (42.1) 
Peritoneal cytology  
  Negative 35 (61.4) 
  Positive 22 (38.6) 
Ovarian metastasis  
  Absent 52 (91.5) 
  Present 5 (8.5) 
Lymph node metastasis  
  Absent 31 (54.3) 
  Present 9 (15.8) 
  Not evaluated 17 (29.8) 
Recurrent disease  
  Absent 36 (63.2) 
  Present 21 (36.8) 
    Local 18 (31.6) 
    Distant 6 (10.5) 
 
Abbreviation: LVSI, lymphovascular space invasion. 
Table 2 Histological type of epithelial component and clinicopathological characters 
 
 Low-grade (n=21) High-grade (n=36) p-value 
Age (median) 58 67  0.002* 
BMI (median) 22.8 23.4 0.912 
p53 expression    
  aberrant (E) 9 (42.9) 27 (75)  0.023* 
  aberrant (M) 10 (47.6) 30 (83.3)  0.007* 
MMR-deficient 5 (23.8) 1 (2.8)  0.022* 
Mesenchymal component   0.565 
  Homologous 9 (42.9) 16 (44.4)  
  Heterologous 12 (57.1) 20 (55.6)  
Stage (III/IV) 9 (42.9) 10 (27.8) 0.261 
Myometrial invasion (> 1/2) 7 (33.3) 15 (41.7) 0.584 
Cervical invasion (present) 4 (19.0) 5 (13.9) 0.712 
LVSI (present) 7 (33.3) 17 (47.2) 0.407 
Peritoneal cytology (positive) 11 (52.4) 11 (30.6) 0.158 
Ovarian metastasis 3 (14.3) 3 (8.3) 0.659 
Lymph node metastasis 3 (14.3) 6 (16.7) 0.564 
Recurrence    
  Local 4 (19.0) 14 (38.9) 0.149 
  Distant 1 (4.8) 5 (13.9) 0.397 
 
Abbreviations: BMI, body mass index; LVSI, lymphovascular space invasion; MMR, mismatch 
repair. 
Table 3 p53 IHC of epithelial component and clinicopathological characters 
 
 p53 wild type (%) 
(n=21) 
p53 aberrant (%) 
(n=36) p-value 
Age (median) 59 67 0.079 
BMI (median) 22.8 23.4 0.908 
Epithelial type    0.023* 
  Low-grade 12 (57.1) 9 (25.0)  
  High-grade 9 (42.9) 27 (75.0)  
Mesenchymal component   0.784 
  Homologous 10 (47.6) 15(41.7)  
  Heterologous 11(52.4) 21 (58.3)  
MMR-deficient 4 (19.0) 2 (5.6) 0.179 
Stage (III/IV) 4 (19.0) 15 (41.7) 0.144 
Myometrial invasion (> 1/2) 7 (33.3) 15 (41.7) 0.584 
Cervical invasion (present) 5 (23.8) 4 (11.1) 0.266 
LVSI (present) 8 (38.1) 16 (44.4) 0.782 
Peritoneal cytology (positive) 7 (33.3) 15 (41.7) 0.584 
Ovarian metastasis 1 (4.8) 5 (13.9) 0.397 
Lymph node metastasis 2 (9.5) 7 (19.4) 0.461 
Recurrence    
  Local 6 (28.6) 12 (33.3) 0.775 
  Distant 2 (9.5) 4 (11.1) 0.851 
 
Abbreviations: BMI, body mass index; IHC, immunohistochemistry; LVSI, lymphovascular 
space invasion; MMR, micmatch repair. 
Table 4 MMR IHC and clinicopathological characters 
 
 MMR-intact (%) (n=51) MMR-deficient (%) (n=6) p-value 
Age (median) 64 57 0.204 
BMI (median) 23 22.1 0.603 
Epithelial type    0.022* 
  Low-grade 16 (31.4) 5 (83.3)  
  High-grade 35 (68.6) 1 (16.7)  
Mesenchymal component   0.388 
  Homologous 21 (41.2) 4 (66.7)  
  Heterologous 30 (58.8) 2 (33.3)  
p53 expression    
  aberrant (E) 38 (74.5) 2 (33.3) 0.058 
  aberrant (M) 34 (66.7) 2 (33.3) 0.179 
Stage (III/IV) 16 (31.4) 3 (50.0) 0.389 
Myometrial invasion (> 1/2) 18 (35.3) 4 (66.7) 0.192 
Cervical invasion (present) 8 (15.7) 1 (16.7) 0.662 
LVSI (present) 21 (41.2) 3 (50.0) 0.689 
Peritoneal cytology (positive) 20 (39.2) 2 (33.3) 0.575 
Ovarian metastasis 5 (9.8) 1 (16.7) 0.504 
Lymph node metastasis 7 (13.7) 2 (33.3) 0.237 
Recurrence    
  Local 18 (35.3) 0 (0) 0.162 
  Distant 5 (9.8) 1 (16.7) 0.504 
 
Abbreviations: BMI, body mass index; IHC, immunohistochemistry; LVSI, lymphovascular 
space invasion; MMR, mismatch repair. 
Table 5.  Prognostic factors for progression-free survival with endometrial carcinosarcoma selected by Cox's univariate analysis 
 
 
Hazard ratio 95%CI p-value 
Age (≧75 year) 1.794 0.695-4.628 0.227 
Epithelial component (High-grade) 3.352 1.124-9.991 0.030* 
Mesenchymal component (Homologous type) 1.559 0.661-3.677 0.31 
Stage (Stage III-IV) 1.821 0.773-4.289 0.17 
Myometrial invasion (> 1/2) 1.135 0.476-2.704 0.776 
Cervical invasion (Present) 0.827 0.244-2.811 0.762 
LVSI (Present) 1.813 0.764-4.305 0.177 
Peritoneal cytology (Present) 1.222 0.514-2.904 0.65 
Ovarian metastasis (Present) 0.891 0.207-3.833 0.877 
Lymph node metastasis (Present) 1.65 0.603-4.512 0.33 
Epithelial component with aberrant expression of p53 1.017 0.410-2.522 0.97 
Mesenchymal component with aberrant expression of p53 1.187 0.570-2.472 0.648 
MMR - intact 3.368 0.450-25.195 0.237 
Abbreviations: LVSI, lymphovascular space invasion; MMR, mismatch repair. 
* p < 0.05 
 
 
